Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
93 hedge funds and large institutions have $405M invested in Syros Pharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 21 increasing their positions, 37 reducing their positions, and 8 closing their positions.
175% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 8
18% more funds holding
Funds holding: 79 → 93 (+14)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
13% less capital invested
Capital invested by funds: $464M → $405M (-$59.6M)
43% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 37
54% less call options, than puts
Call options by funds: $11K | Put options by funds: $24K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$30.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$9.71M |
| 3 |
CIA
Capital Impact Advisors
Boston,
Massachusetts
|
+$1.92M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.5M |
| 5 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$878K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.95M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$6.16M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$6.04M |
| 4 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$2.27M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.86M |
SYRS Hedge Fund Activity: Q3 2020 in Review
93 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q3 2020, worth a combined $405M — down 13% from $464M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SYRS positions and 8 closed out — a net gain of 14 holders — while 21 added to existing stakes and 37 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $30.7M. The largest seller was Point72 Asset Management, cutting an estimated $9.95M.
- 93 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q3 2020, up from 79 in Q2 2020.
- Funds reported $405M of Syros Pharmaceuticals, Inc. Common Stock stock for Q3 2020, down 13% quarter-over-quarter.
- 22 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q3 2020 and 8 closed out, a net change of +14 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q3 2020 was ARK Investment Management, an estimated $30.7M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q3 2020 was Point72 Asset Management, an estimated $9.95M sold.
Based on aggregated 13F filings for Q3 2020.